|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Interventional treatment for unresectable hepatocellular carcinoma显示文摘Hepatocellular carcinoma(HCC) is the sixth most common cancer and third leading cause of cancer-related death in the world. The Barcelona clinic liver cancer classification is the current standard classification system for the clinical management of patients with HCC and suggests that patients with intermediate-stage HCC benefit from transcatheter arterial chemoembolization(TACE). Interventional treatments such as TACE, balloon-occluded TACE, drug-eluting bead embolization, radioembolization, and combined therapies including TACE and radiofrequency ablation, continue to evolve, resulting in improved patient prognosis. However, patients with advanced-stage HCC typically receive only chemotherapy with sorafenib, a multi-kinase inhibitor, or palliative and conservative therapy. Most patients receive palliative or conservative therapy only, and approximately 50% of patients with HCC are candidatesfor systemic therapy. However, these patients require therapy that is more effective than sorafenib or conservative treatment. Several researchers try to perform more effective therapies, such as combined therapies(TACE with radiotherapy and sorafenib with TACE), modified TACE for HCC with arterioportal or arteriohepatic vein shunts, TACE based on hepatic hemodynamics, and isolated hepatic perfusion. This review summarizes the published data and data on important ongoing studies concerning interventional treatments for unresectable HCC and discusses the technical improvements in these interventions, particularly for advanced-stage HCC. | Satoru Murata Takahiko Mine Fumie Sugihara Daisuke Yasui Hidenori Yamaguchi Tatsuo Ueda Shiro Onozawa Shin-ichiro Kumita | 2014 | World Journal of Gastroenterology2014，20，37： | 38 |
| 2 | Apoptosis and non-alcoholic fatty liver diseases显示文摘The number of patients with nonalcoholic fatty liver diseases(NAFLD) including nonalcoholic steatohepatitis(NASH), has been increasing. NASH causes cirrhosis and hepatocellular carcinoma(HCC) and is one of the most serious health problems in the world. The mechanism through which NASH progresses is still largely unknown. Activation of caspases, Bcl-2 family proteins, and c-Jun N-terminal kinase-induced hepatocyte apoptosis plays a role in the activation of NAFLD/NASH. Apoptotic hepatocytes stimulate immune cells and hepatic stellate cells toward the progression of fibrosis in the liver through the production of inflammasomes and cytokines. Abnormalities in glucose and lipid metabolism as well as microbiota accelerate these processes. The production of reactive oxygen species, oxidative stress, and endoplasmic reticulum stress is also involved. Cell death, including apoptosis, seems very important in the progression of NAFLD and NASH. Recently, inhibitors of apoptosis have been developed as drugs for the treatment of NASH and may prevent cirrhosis and HCC. Increased hepatocyte apoptosis may distinguish NASH from NAFLD, and the improvement of apoptosis could play a role in controlling the development of NASH. In this review, the association between apoptosis and NAFLD/NASH are discussed. This review could provide their knowledge, which plays a role in seeing the patients with NAFLD/NASH in daily clinical practice. | Tatsuo Kanda Shunichi Matsuoka Motomi Yamazaki Toshikatsu Shibata Kazushige Nirei Hiroshi Takahashi Tomohiro Kaneko Mariko Fujisawa Teruhisa Higuchi Hitomi Nakamura Naoki Matsumoto Hiroaki Yamagami Masahiro Ogawa Hiroo Imazu Kazumichi Kuroda Mitsuhiko Moriyama | 2018 | World Journal of Gastroenterology2018，24，25： | 32 |
| 3 | Process Modeling for Heat Treatment: Current Status and Future Developments显示文摘Heat Treating is a critical manufacturing technology. This is particularly true in countries with large manufacturing industry including:; automotive, construction, transportation, and aerospace sectors. Technical advancement of the heat treating industry will be a critical component of the increasing need to remain competitive in this manufacturing sector on a global scale. ASM International has identified the development of process modeling and numerical simulation as a critical technology for the advancement of the heat treating process industry. In this paper, a selective overview of the current accomplishments and future needs of process modeling technologies in heat treatment will be provided. | Tatsuo Inoue, Kiyoshi Funatani and George E. Totters 1.Department of Energy Conversion Science, Kyoto University, Kyoto, Japan 2.Nihan Parkurizing Co., Ltd., Nagoya, Japan 3.Union Carbide Corporation, Tarrytown, NY, USA | 2000 | Journal of Shanghai Jiaotong university(Science)2000，5，1： | 23 |
| 4 | Nonalcoholic fatty liver disease and hepatic cirrhosis: comparison with viral hepatitis-associated steatosis显示文摘Nonalcoholic fatty liver disease(NAFLD) including nonalcoholic steatohepatitis(NASH) is globally increasing and has become a world-wide health problem. Chronic infection with hepatitis B virus or hepatitis C virus(HCV) is associated with hepatic steatosis. Viral hepatitis-associated hepatic steatosis is often caused by metabolic syndrome including obesity,type 2 diabetes mellitus and/or dyslipidemia. It has been reported that HCV genotype 3 exerts direct metabolic effects that lead to hepatic steatosis. In this review,the differences between NAFLD/NASH and viral hepatitis-associated steatosis are discussed. | Yuki Haga Tatsuo Kanda Reina Sasaki Masato Nakamura Shingo Nakamoto Osamu Yokosuka | 2015 | World Journal of Gastroenterology2015，21，46： | 20 |
| 5 | Importance of adequate immunosuppressive therapy for the recovery of patients with 'life-threatening' severe exacerbation of chronic hepatitis B显示文摘AIM: Hepatitis B virus (HBV) re-activation often occurs spontaneously or after withdrawal of immunosuppressive therapy in patients with chronic hepatitis B. Severe exacerbation, sometimes developing into fulminant hepatic failure, is at high risk of mortality. The efficacy of corticosteroid therapy in 'clinically severe' exacerbation of chronic hepatitis B has not been well demonstrated. In this study we evaluated the efficacy of early introduction of high-dose corticosteroid therapy in patients with lifethreatening severe exacerbation of chronic hepatitis B.METHODS: Twenty-two patients, 14 men and 8 women,were defined as 'severe' exacerbation of chronic hepatitis B using uniform criteria and enrolled in this study. Eleven patients were treated with corticosteroids at 60 mg or more daily with or without anti-viral drugs within 10 d after the diagnosis of severe disease ('early high-dose'group) and 11 patients were either treated more than 10 d or untreated with corticosteroids ('non-early high-dose'group).RESULTS: Mean age, male-to-female ratio, mean prothrombin time (PT) activity, alanine transaminase (ALT)level, total bilirubin level, positivity of HBeAg, mean IgMHBc titer, and mean HBV DNA polymerase activity did not differ between the two groups. Ten of 11 patients of the 'early high-dose' group survived, while only 2 of 11 patients of the 'non-early high-dose' group survived (P<0.001). During the first 2 wk after the introduction of corticosteroids, improvements in PT activities and total bilirubin levels were observed in the 'early high-dose'group. Both ALT levels and HBV DNA polymerase levels fell in both groups.CONCLUSION: The introduction of high-dose corticosteroid can reverse deterioration in patients with 'clinically lifethreatening' severe exacerbation of chronic hepatitis B,when used in the early stage of illness. | Keiichi Fujiwara Osamu Yokosuka Hiroshige Kojima Tatsuo Kanda Hiromitsu Saisho Hiroyuki Hirasawa Hiroshi Suzuki | 2005 | World Journal of Gastroenterology2005，11，8： | 20 |
| 6 | Laparoscopic appendectomy for acute appendicitis: How to discourage surgeons using inadequate therapy显示文摘Acute appendicitis(AA) develops in a progressive and irreversible manner, even if the clinical course of AA can be temporarily modified by intentional medications. Reliable and real-time diagnosis of AA can be made based on findings of the white blood cell count and enhanced computed tomography. Emergent laparoscopic appendectomy(LA) is considered as the first therapeutic choice for AA. Interval/delayed appendectomy at 6-12 wk after disease onset is considered as unsafe with a high recurrent rate during the waiting time. However, this technique may have some advantages for avoiding unnecessary extended resection in patients with an appendiceal mass. Nonoperative management of AA may be tolerated only in children. Postoperative complications increase according to the patient's factors, and temporal avoidance of emergent general anesthesia may be beneficial for high-risk patients. The surgeon's skill and cooperation of the hospital are important for successful LA. Delaying appendectomy for less than 24 h from diagnosis is safe. Additionally, a semi-elective manner(i.e., LA within 24 h after onset of symptoms) may be paradoxically acceptable, according to the factors of the patient, physician, and institution. Prompt LA is mandatory for AA. Fortunately, the Japanese government uses a universal health insurance system, which covers LA. | tomohide hori takafumi machimoto yoshio kadokawa toshiyuki hata tatsuo ito shigeru kato daiki yasukawa yuki aisu yusuke kimura maho sasaki yuichi takamatsu taku kitano shigeo hisamori tsunehiro yoshimura | 2017 | World Journal of Gastroenterology2017，23，32： | 18 |
| 7 | Antiviral therapies for chronic hepatitis C virus infection with cirrhosis显示文摘Patients who are infected with hepatitis C virus(HCV) and also have advanced fibrosis or cirrhosis have beenrecognized as 'difficult-to-treat' patients during an era when peginterferon and ribavirin combination therapy is the standard of care. Recent guidelines have clearly stated that treatment should be prioritized in this population to prevent complications such as decompensation and hepatocellular carcinoma. Recent advances in the treatment of chronic hepatitis C have been achieved through the development of direct-acting antiviral agents(DAAs). Boceprevir and telaprevir are first-generation DAAs that inhibit the HCV NS3/4A protease. Boceprevir or telaprevir, in combination with peginterferon and ribavirin, improved the sustained virological response rates compared with peginterferon and ribavirin alone and were tolerated in patients with HCV genotype 1 infection without cirrhosis or compensated cirrhosis. However, the efficacy is lower especially in prior non-responders with or without cirrhosis. Furthermore, a high incidence of adverse events was observed in patients with advanced liver disease, including cirrhosis, in real-life settings. Current guidelines in the United States and in some European countries no longer recommend these regimens for the treatment of HCV. Next-generation DAAs include second-generation HCV NS3/4A protease inhibitors, HCV NS5 A inhibitors and HCV NS5 B inhibitors, which have a high efficacy and a lower toxicity. These drugs are used in interferon-free or in interferon-based regimens with or without ribavirin in combination with different classes of DAAs. Interferon-based regimens, such as simeprevir in combination with peginterferon and ribavirin, are well tolerated and are highly effective especially in treatmentnave patients and in patients who received treatment but who relapsed. The efficacy is less pronounced in nullresponders and in patients with cirrhosis. Interferonfree regimens in combination with ribavirin and/or two or more DAAs could be used for treatment-nave, treatment-experienced and even for interferon-ineligible or interferon-intolerant patients. Some clinical trials have demonstrated promising results, and have shown that the efficacy and safety were not different between patients with and without cirrhosis. There are also promising regimens for genotypes other than genotype 1. Interferonis contraindicated in patients with decompensated cirrhosis, and further studies are needed to establish the optimal treatment regimen for this population. In the future, interferon-free and ribavirin-free regimens with high efficacy and improved safety are expected for HCVinfected patients with advanced liver diseases. | Shingo Nakamoto Tatsuo Kanda Hiroshi Shirasawa Osamu Yokosuka | 2015 | World Journal of Hepatology2015，7，8： | 17 |
| 8 | Current and future directions for treating hepatitis B virus infection显示文摘Hepatitis B virus(HBV) persistently infects approximately 350 million people, and approximately 600000 liverrelated deaths are observed per year worldwide. HBV infection is also one of the major risk factors for hepatocellular carcinoma(HCC). The persistence of serum hepatitis B e antigen(HBe Ag) and high level of serum HBV DNA are thought to reflect a high HBV replication status in hepatocytes, causing cirrhosis, HCC and liver-related deaths. It has been reported that antiviral therapy, such as peginterferon and nucleos(t)ide analogues(NUCs), could suppress liver-related death by inhibiting the HBV DNA levels and inducing seroconversion from HBe Ag to antibody to HBe antigen. Currently, peginterferon is widely used, but there are also several disadvantages in the use of peginterferon, such as various adverse events, the administration route and duration. It is difficult to predict the effects of treatment and interferon is contraindicated for the patients with advanced fibrosis of the liver and cirrhosis. With respect to NUCs, entecavir and tenofovir disoproxil fumarate are current the first-choice drugs. NUCs can be administered orally, and their anti-viral effects are stronger than that of peginterferon. However, because cessation of NUC administration leads to high levels of viral replication and causes severe hepatitis, they must be administered for a long time. On the other hand, the use of both interferon and NUCs cannot eliminate covalently closed circular DNA of HBV. In this review, we evaluate the natural course of chronic HBV infection and then provide an outline of these representative drugs, such as peginterferon, entecavir and tenofovir disoproxil fumarate. | Akinobu Tawada Tatsuo Kanda Osamu Yokosuka | 2015 | World Journal of Hepatology2015，7，11： | 16 |
| 9 | Current management of patients with hepatocellular carcinoma显示文摘The current management therapies for hepatocellular carcinoma(HCC) patients are discussed in this review. Despite the development of new therapies, HCC remains a 'difficult to treat' cancer because HCC typically occurs in advanced liver disease or hepatic cirrhosis. The progression of multistep and multicentric HCC hampers the prevention of the recurrence of HCC. Many HCC patients are treated with surgical resection and radiofrequency ablation(RFA), although these modalities should be considered in only selected cases with a certain HCC number and size. Although there is a shortage of grafts, liver transplantation has the highest survival rates for HCC. Several modalities are salvage treatments; however, intensive care in combination with other modalities or in combination with surgical resection or RFA might offer a better prognosis. Sorafenib is useful for patients with advanced HCC. In the near future, HCC treatment will include stronger molecular targeted drugs, which will have greater potency and fewer adverse events. Further studies will be ongoing. | Tatsuo Kanda Sadahisa Ogasawara Tetsuhiro Chiba Yuki Haga Masao Omata Osamu Yokosuka | 2015 | World Journal of Hepatology2015，7，15： | 15 |
| 10 | Hepatitis C virus NS5A inhibitors and drug resistance mutations显示文摘Some direct-acting antiviral agents for hepatitis C virus(HCV),such as telaprevir and boceprevir have been available since 2011.It was reported that HCV NS5A is associated with interferon signaling related to HCV replication and hepatocarcinogenesis.HCV NS5A inhibitors efficiently inhibited HCV replication in vitro.Human studies showed that dual,triple and quad regimens with HCV NS5A inhibitors,such as daclatasvir and ledipasvir,in combination with other direct-acting antiviral agents against other regions of HCV with or without peginterferon/ribavirin,could efficiently inhibit HCV replication according to HCV genotypes.These combinations might be a powerful tool for'difficult-to-treat'HCV-infected patients.'First generation'HCV NS5A inhibitors such as daclatasvir,ledipasvir and ABT-267,which are now in phaseⅢclinical trials,could result in resistance mutations.'Second generation'NS5A inhibitors such as GS-5816,ACH-3102,and MK-8742,have displayed improvements in the genetic barrier while maintaining potency.HCV NS5A inhibitors are safe at low concentrations,which make them attractive for use despite low genetic barriers,although,in fact,HCV NS5A inhibitors should be used with HCV NS3/4A inhibitors,HCV NS5B inhibitors or peginterferon plus ribavirin.This review article describes HCV NS5A inhibitor resistance mutations and recommends that HCV NS5A inhibitors be used in combination regimens potent enough to prevent the emergence of resistant variants. | Shingo Nakamoto Tatsuo Kanda Shuang Wu Hiroshi Shirasawa Osamu Yokosuka | 2014 | World Journal of Gastroenterology2014，20，11： | 12 |
| 11 | Dispersoid Formation and Recrystallization Behavior in an Al-Mg-Si-Mn Alloy显示文摘The nucleation and precipitation of Mn-containing dispersoids in an Al-Mg-Si-Mn alloy (6082) have been studied by optical microscopy,EPMA (electron probe microanalysis) and TEM (transmission electron microscopy).The influence of Mn-containing dispersoids on the recrystallization behavior was also investigated.The size and distribution of dispersoids were strongly affected by both the homogenization process and the alloying element distribution formed in the direct chill cast procedure.The Mn-containing dispersoids were observed to nucleate preferentially on the β-Mg 2 Si phase and to be aligned along the <100> direction of the matrix.After cold deformation,the morphology of dispersoids greatly influences the recrystallization and grain growth behavior in the annealing process. | Rong Hu Tomo Ogura Hiroyasu Tezuka Tatsuo Sato Qing Liu | 2010 | Journal of Materials Science & Technology2010，26，3： | 10 |
| 12 | Management of a large mucosal defect after duodenal endoscopic resection显示文摘Duodenal endoscopic resection is the most difficult type of endoscopic treatment in the gastrointestinal tract(GI) and is technically challenging because of anatomical specificities. In addition to these technical difficulties, this procedure is associated with a significantly higher rate of complication than endoscopic treatment in other parts of the GI tract. Postoperative delayed perforation and bleeding are hazardous complications, and emergency surgical intervention is sometimes required. Therefore, it is urgently necessary to establish a management protocol for preventing serious complications. For instance, the prophylactic closure of large mucosal defects after endoscopic resection may reduce the risk of hazardous complications. However, the size of mucosal defects after endoscopic submucosal dissection(ESD) is relatively large compared with the size after endoscopic mucosal resection, making it impossible to achieve complete closure using only conventional clips. The over-the-scope clip and polyglycolic acid sheets with fibrin gel make it possible to close large mucosal defects after duodenal ESD. In addition to the combination of laparoscopic surgery and endoscopic resection, endoscopic full-thickness resection holds therapeutic potential for difficult duodenal lesions and may overcome the disadvantages of endoscopic resection in the near future. This review aims to summarize the complications and closure techniques of large mucosal defects and to highlight some directions for management after duodenal endoscopic treatment. | Shintaro Fujihara Hirohito Mori Hideki Kobara Noriko Nishiyama Tae Matsunaga Maki Ayaki Tatsuo Yachida Tsutomu Masaki | 2016 | World Journal of Gastroenterology2016，22，29： | 10 |
| 13 | Androgen receptor signaling in hepatocellular carcinoma and pancreatic cancers显示文摘Hepatocellular carcinoma(HCC)and pancreatic cancer remain difficult to treat,and despite the ongoing development of new treatments,the overall survival rate has only modestly improved over the past decade.Liver and pancreatic progenitors commonly develop from endoderm cells in the embryonic foregut.A previous study showed that HCC and pancreatic cancer cell lines variably express androgen receptor(AR),and these cancers and the surrounding tissues also express AR.AR is a ligand-dependent transcription factor that belongs to the nuclear receptor superfamily.Androgen response element is present in regulatory elements on the AR-responsive target genes,such as transforming growth factor beta-1(TGF beta-1)and vascular endothelial growth factor(VEGF).It is well known that the activation of AR is associated with human carcinogenesis in prostate cancer as well as HCC and pancreatic cancer and that GRP78,TGF beta,and VEGF all play important roles in carcinogenesis and cancer development in these cancers.HCC is a male-dominant cancer irrespective of its etiology.Previous work has reported that vertebrae forkhead box A 1/2 are involved in estrogen receptors and/or AR signaling pathways,which may contribute to the gender differences observed with HCC.Our recent work also showed that AR has a critical role in pancreatic cancer development,despite pancreatic cancer not being a male dominant cancer.Aryl hydrocarbon(or dioxin)receptor is also involved in both HCC and pancreatic cancer through the formation of complex with AR.It is possible that AR might be involved in their carcinogenesis through major histocompatibility complex classⅠchain-related gene A/B.This review article describes AR and its role in HCC and pancreatic cancer and suggests that more specific AR signaling-inhibitors may be useful in the treatment of these'difficult to treat'cancers. | Tatsuo Kanda Xia Jiang Osamu Yokosuka | 2014 | World Journal of Gastroenterology2014，20，28： | 9 |
| 14 | Reduction effect of bacterial counts by preoperative saline lavage of the stomach in performing laparoscopic and endoscopic cooperative surgery显示文摘AIM:To investigate the effects of gastric lavage with2000 mL of saline in laparoscopic and endoscopic cooperative surgery.METHODS:Twenty two patients who were diagnosed with a gastric gastrointestinal stromal tumor were enrolled.In former term,irrigations of the stomach were conducted whenever it was necessary,not systematically(Non systemic lavage group).In latter term,the stomach was thoroughly cleaned with 2000 mL of saline using an endoscope with a water jet,and Duodenal balloon occlusion was conducted to prevent refluxedbile and pancreatic juice(Systemic lavage+balloon occlusion group).The gastric wall was sprayed with 20mL of distilled water,and 20 mL of gastric juice was collected in a sterile tube and submitted for culture.20mL of ascites was also collected from the laparoscopic ports and submitted for culture.We compared WBC,CRP,BT between two groups,and verify the reduction effect of bacterial counts in Systemic lavage+balloon occlusion group.RESULTS:WBC count before,1 d after,and 3 d after laparoscopic and endoscopic cooperative surgery(LECS)were 5060(95%CI:4250-9640),12140(6050-14110),and 6910(5320-12520)in Non systemic lavage group,4400(3660-7620),8910(6480-10980),and 5950(4840-7860)in Systemic lavage+balloon occlusion group.Significant differences between two groups at the day after LECS(P=0.029)and the 3 d after LECS(P=0.042).CRP levels in Non systemic lavage group and in Systemic lavage+balloon occlusion group were significantly different at the day after LECS(P=0.005)and the 3 d after LECS(P=0.028).BTs(℃)in Non systemic lavage group and in Systemic lavage+balloon occlusion group were also significantly different at the day after LECS(P=0.004)and the 3 d after LECS(P=0.006).In a logarithmic comparison,bacterial load before gastric lavage,after lavage,and ascites culture were 6.08(95%CI:4.04-6.97),0.48(0-0.85),and 0.21(0-0.56).The bacterial counts before and after gastric lavage were significantly suppressed(P=0.007),but no significant difference between gastric juice culture after lavage and ascites(P=0.154).CONCLUSION:Pre-LECS lavage with 2000 mL of saline exhibited a bacteria-reducing effect equivalent to disinfectants and obtained favorable results in terms of clinical symptoms and data. | Hirohito Mori Hideki Kobara Takaaki Tsushimi Shintaro Fujihara Noriko Nishiyama Tae Matsunaga Maki Ayaki Tatsuo Yachida Joji Tani Hisaaki Miyoshi Asahiro Morishita Tsutomu Masaki | 2014 | World Journal of Gastroenterology2014，20，42： | 9 |
| 15 | Effects of adacolumn selective leukocytapheresis on plasma cytokines during active disease in patients with active ulcerative colitis显示文摘瞄准:调查在临床的活动索引的 ulcerative (UC )( 蔡) 和 IL-1ra, IL-10, IL-6 和 IL-18 的传播层次之间的关系。方法:IL-1ra, IL-10, IL-6 和 IL-18 的血层次与活跃 UC 在 31 个病人被测量,吝啬的蔡是 11.1,从 5-25 ;并且是的 12 个健康个人控制。病人们与 Adacolumn 被给粒细胞和单核白血球 adsorptive 词首字母的脱落(GMA ) 。忍受 FcgammaR 并且补充受体的白细胞被吸附到列 leucocytapheresis 搬运人。每个病人能在 8 wk 上收到多达 11 个 GMA 会议。结果:我们发现了在蔡和 IL-10 之间的强壮的关联(r = 0.827, P <
0.001 ) , IL-6 (r = 0.785, P <
0.001 ) 并且 IL-18 (r = 0.791, P <
0.001 ) 。IL-1ra 没与蔡一起被相关。后面的 GMA 治疗, 31 个病人中的 24 个完成了宽恕,所有 4 cytokines 的层次掉在健康控制里到层次。进一步, IL-1ra 和 IL-10 的血层次在从遵守了搬运人的白细胞建议版本的 60 min 在列流出和流入增加了。 | Hiroyuki Hanai Takayuki Iida Masami Yamada Yoshihiko Sato Ken Takeuchi Tatsuo Tanaka Kenji Kondo Masataka Kikuyama Yasuhiko Maruyama Yasushi Iwaoka Akiko Nakamura Kazuhisa Hirayama Abby R Saniabadi Fumitoshi Watanabe | 2006 | World Journal of Gastroenterology2006，12，21： | 8 |
| 16 | Roles of the Y chromosome genes in human cancers显示文摘男性和女性由他们的各自的性染色体作文遗传上不同,也就是说同样男性的 XY 和 XX 作为女性。尽管 X 和 Y 染色体从正染色体的一样的祖先对演变, Y 染色体怀有男性特定的基因,它在各种各样的纸巾的男性决心,细菌房间区别,和 masculinization 起枢轴的作用。决定性的基因的删除或 translocation, SRY,从 Y,染色体引起性开发的混乱(以前作为一个间性条件称为) 与劣生的性腺。gonadal 开发的失败不孕导致不仅,而且在细菌房间肿瘤(GCT ) 的增加的风险,例如 gonadoblastoma 和阴囊的 GCT 的各种各样的类型。最近的研究证明 Y 染色体或 Y 染色体基因的宫外的表示的任何一个损失仔细与各种各样的偏导男性的疾病被联系,包括选择体的癌症。这些观察比期望建议连接 Y 的基因经常在更多涉及男健康和疾病。尽管仅仅编码蛋白质的基因的一个小数字在 Y 染色体的男性特定的区域是在场的,人的疾病上的 Y 染色体基因的影响大部分仍然是未知的,由于缺乏在在人和啮齿类动物的 Y 染色体之间的 vivo 模型和差别。在这评论,我们在人在癌症开发加亮选择 Y 染色体基因的参与。 | Tatsuo Kido Yun-Fai Chris Lau | 2015 | Asian Journal of Andrology2015，17，3： | 8 |
| 17 | Evaluation of the relationship between hepatocellular carcinoma location and transarterial chemoembolization efficacy显示文摘AIM To evaluate the relationship between the location of hepatocellular carcinoma(HCC) and the efficacy of transarterial chemoembolization(TACE).METHODS We evaluated 115 patients(127 nodules), excluding recurrent nodules, treated with TACE between January 2011 and June 2014. TACE efficacy was evaluated according to m RECIST. The HCC location coefficient was calculated as the distance from the central portal portion to the HCC center(mm)/liver diameter(mm) on multiplanar reconstruction images rendered(MPR) to visualize bifurcation of the right and left branches of the portal vein and HCC center. The HCC location coefficient was compared between complete response(CR) and non-CR groups in Child-Pugh grade A and B patients.RESULTS The median location coefficient of HCC among all nodules, the right lobe, and the medial segment was significantly higher in the CR group than in the non-CR group in the Child-Pugh grade A patients(0.82 vs 0.62, P < 0.001; 0.71 vs 0.59, P < 0.01; 0.81 vs 0.49, P < 0.05, respectively). However, there was no significant difference in the median location coefficient of the HCC in the lateral segment between in the CR and in the non-CR groups(0.67 vs 0.65, P > 0.05). On the other hand, in the Child-Pugh grade B patients, the HCC median location coefficient in each lobe and segment was not significantly different between in the CR and in the non-CR groups.CONCLUSION Improved TACE efficacy may be obtained for HCC in the peripheral zone of the right lobe and the medial segment in Child-Pugh grade A patients. | Izumi Miki Satoru Murata Fumio Uchiyama Daisuke Yasui Tatsuo Ueda Fumie Sugihara Hidemasa Saito Hidenori Yamaguchi Ryusuke Murakami Chiaki Kawamoto Eiji Uchida Shin-ichiro Kumita | 2017 | World Journal of Gastroenterology2017，23，35： | 8 |
| 18 | APASL consensus statements and management algorithms for hepatitis C virus infection显示文摘 | Masao Omata Tatsuo Kanda Ming-Lung Yu Osamu Yokosuka Seng-Gee Lim Wasim Jafri Ryosuke Tateishi Saeed S. Hamid Wan-Long Chuang Anuchit Chutaputti Lai Wei Jose Sollano Shiv Kumar Sarin Jia-Horng Kao Geoffrey W. McCaughan | 2012 | Hepatology International2012，，2： | 8 |
| 19 | Decrease of reactive-oxygen-producing granulocytes and release of IL-10 into the peripheral blood following leukocytapheresis in patients with active ulcerative colitis显示文摘AIM: To investigate the clinical efficacy of leukocytapheresis (LCAP) in patients with active ulcerative colitis (UC), and to elucidate the mechanisms by determining the changes in the cytokine levels in the peripheral blood and of the functions of the peripheral blood leukocytes in these patients.METHODS: The subjects were 19 patients with active UC, with a mean clinical activity index (CAI) of 9.2. The LCAP was conducted using Cellsorba E. In each session of LCAP, 2-3 L of blood at the flow rate of 30-50 mL/min was processed. The treatment was carried out in approximately 1-h sessions, once a week, for 5-10 wk. Blood samples for determination of the cytokine levels were collected from the inflow side of the column (site of dehematization; at the start of LCAP) and outflow side of the column (at the end of LCAP). Blood samples for the determination of reactive-oxygen-producing cells were collected from the peripheral blood before and after LCAP.RESULTS: LCAP resulted in clinical improvement in all the 19 patients of UC recruited for this study. Remission (CAI: ≤4) was noted in 15 (79%) of the 19 patients. The blood level of the pro-inflammatory cytoline IL-6 was found to be decreased following treatment by LCAP, and the level of the anti-inflammatory cytokine IL-10 at the outflow side of the LCAP column was found to be significantly elevated as compared to that at the inflow side of the column. The reactive-oxygen-producing granulocytes in the peripheral blood of UC patients was increased as compared to that in healthy persons and the increase was found to be decreased following treatment by LCAP.CONCLUSION: LCAP exerted a high therapeutic efficacy in patients with active UC. Our findings suggest that LCAP is associated with enhanced production of the inhibitory cytokine IL-10 to indirectly inhibit the functions of the inflammatory leukocytes, and that inflammation is also considerably attenuated by the direct removal of reactiveoxygen-producing neutrophils from the peripheral blood. | Hiroyuki Hanai Takayuki Iida Ken Takeuchi Fumitoshi Watanabe Yasuhiko Maruyama Masataka Kikuyama Tatsuo Tanaka Kenji Kondo Kou Tanaka Kenji Takai | 2005 | World Journal of Gastroenterology2005，11，20： | 7 |
| 20 | Endobronchial metastasis from adenocarcinoma of gastric cardia 7 years after potentially curable resection显示文摘Endobronchial metastasis(EBM) is a rare form of metas-tasis from extrapulmonary malignant tumors,although there are few reports of EBM from gastric cancer specifically.We report the case of a 51-year-old woman who had undergone gastrectomy for advanced gastric cancer seven years previously but was diagnosed with a solitary lung tumor by follow-up computed tomography.On diagnosis of primary lung cancer,she underwent pulmonary lobectomy,but immunohistochemical examination confirmed the resected tumor to be an EBM from the gastric cancer.Six months later,she was diagnosed with peritoneal metastases and underwent chemotherapy with gastric cancer regimen.She is still alive at 33 mo after the lobectomy.Generally,the prognosis for EBM is poor although multidisciplinary treatment can lead to long-term survival.Precise diagnosis on the basis of detailed pathological and immunohistochemical evaluation can contribute to deciding the most effective treatment and improving prognosis. | Takaaki Hanyu Tatsuo Kanda Atsushi Matsuki Go Hasegawa Kazuhito Yajima Masanori Tsuchida Shin-ichi Kosugi Makoto Naito Katsuyoshi Hatakeyama | 2010 | World Journal of Gastrointestinal Surgery2010，2，8： | 7 |
您所在的机构暂未开通此部分的功能，请联系管理员